γ-Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer-Related Pathologies in a Mouse Model of Down Syndrome.

Xu-Qiao ChenAnn BeckerRicardo AlbayPhuong D NguyenDmitry KarachentsevAmanda J RobertsKevin D RynearsonRudolph E TanziWilliam C Mobley

Published in: Annals of neurology (2024)

Our findings point to the involvement of increased levels of Aβ42 and/or Aβ40 in contributing to several molecular and cognitive traits associated with DS-AD. They speak to increased dosage of the APP gene acting through heightened levels of Aβ42 and/or Aβ40 as supporting pathogenesis. These findings further the interest in the potential use of γ-secretase modulators for treating and possibly preventing AD in individuals with DS. ANN NEUROL 2024;96:390-404.

Keyphrases

mouse model
genome wide
small molecule
copy number
cognitive decline
gene expression
neural network
genome wide identification